MedTrace Logo

The Effect of Raltegravir on HIV Decay During Primary and Chronic Infection

NCT00641641 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2017-08-31

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to measure the decay characteristics of HIV in the blood of patients after taking a combination of anti-HIV drugs, which includes a new class of anti-HIV drug, an integrase inhibitor. This study explores how this new combination of therapy reduces virus in various compartments of the body and immune system.

Conditions

  • HIV Infection

Interventions

DRUG

Tenofovir + emtricitabine + raltegravir.

TDF 300mg once daily + FTC 200mg once daily + RAL 400mg twice daily.

Sponsors & Collaborators

Principal Investigators

  • Anthony Kelleher, MBBS (Hons) PhD, FRACP, FRCPA · Kirby Institute

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-03-31
Primary Completion
2011-03-31
Completion
2011-06-30

Countries

  • Australia

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00641641 on ClinicalTrials.gov